Immunotherapy Paradigm Continues to Evolve in NSCLC – OncLive
OncLive |
Immunotherapy Paradigm Continues to Evolve in NSCLC
OncLive Recent approval of immunotherapy in the first-line setting for treatment of patients with locally advanced and metastatic non–small cell lung cancer (NSCLC) without driver mutations represents “a fundamental change in care,” according to Mark G. Kris, MD. |
